Luminescent oxygen channeling assay (LOCI): sensitive, broadly applicable homogeneous immunoassay method

Ullman, Edwin F.; Kirakossian, Hrair; Switchenko, Arthur C.; Ishkanian, Jacqueline; Ericson, Marica B.; Wartchow, Charles; Pirio, Marcel R.; Pease, John; Irvin, Benjamin R.; Singh, Sharat; Singh, Rajendra; Patel, Rajesh; Dafforn, Alan; Davalian, Dariush; Skold, C N; Kurn, Nurith; Wagner, Daniel B.

doi:10.1093/clinchem/42.9.1518

Cited by 231 publications

(101 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An amplified luminescent proximity homogeneous assay is based on a luminescent oxygen‐channeling chemistry 58 . In this assay, an analyte is sandwiched by a biotinylated Ab conjugated to streptavidin‐coated donor beads and a second Ab conjugated to acceptor beads.…”

Section: Development Of High‐throughput Screening Methodsmentioning

confidence: 99%

Targeting DNA binding proteins for cancer therapy

et al. 2020

View full text Add to dashboard Cite

Yoshitomo Shiroma and Ryou-u Takahashi contributed equally to this work.Abbreviations: AEP, AF4 family/ENL family/P-TEFb; ARNT, aryl hydrocarbon receptor nuclear translocator; BRD4, bromodomain-containing protein 4; CBP, CREB-binding protein; DUX4, double homeobox protein 4; ETO, eight-twenty one; EWS, Ewing's sarcoma; FLI1, friend leukemia virus integration 1; HIF, hypoxia-inducible factor; MLL, mixed-lineage leukemia; SOX2, Sry-related high-mobility box 2; STAT3, signal transducer and activator of transcription 3; TF, transcription factor; TRF, telomere-repeat binding factor. AbstractDysregulation or mutation of DNA binding proteins such as transcription factors (TFs) is associated with the onset and progression of various types of disease, including cancer. Alteration of TF activity occurs in numerous cancer tissues due to gene amplification, deletion, and point mutations, and epigenetic modification. Although cancer-associated TFs are promising targets for cancer therapy, development of drugs targeting these TFs has historically been difficult due to the lack of high-throughput screening methods. Recent advances in technology for identification and selective inhibition of DNA binding proteins enable cancer researchers to develop novel therapeutics targeting cancer-associated TFs. In the present review, we summarize known cancer-associated TFs according to cancer type and introduce recently developed high-throughput approaches to identify selective inhibitors of cancer-associated TFs. K E Y W O R D SDNA binding protein, drug discovery, high-throughput screening, telomere, transcription factor | 1059 SHIROMA et Al.

show abstract

Section: Development Of High‐throughput Screening Methodsmentioning

confidence: 99%

Targeting DNA binding proteins for cancer therapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Serum samples were analyzed for IAsp using a LOCI™ technology based assay [16] with the same antibodies as the published ELISA [13] and using human serum calibrators in the analysis. The LOCI™ based assay gave a good correlation (y = 1.05 × x − 0.33, r 2 = 0.79) to the ELISA up to the approximate concentration of 80 pM.…”

Section: Analysis Of Serum Iaspmentioning

confidence: 99%

Pharmacokinetics following continuous subcutaneous insulin infusion of insulin aspart with or without initial subcutaneous bolus

Petersen

Nielsen

Søndergaard

et al. 2010

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…The shorter emission wavelength ensures very low background and potentially very high assay sensitivity. 80,81 The technology is also very versatile as it utilizes diffusion of singlet oxygen, which enables measurement of significantly larger biomolecular complexes (up to 200 nm) than possible with Förster-type resonance energy transfer. The particle pair formation, however, can be unfavorable in some applications due to steric and kinetic issues, and the singlet oxygen is known to be susceptible to chemical quenching in biological samples.…”

Section: Upconversion Fluorescence Resonance Energy Transfermentioning

confidence: 99%

Photon Upconversion in Homogeneous Fluorescence‐based Bioanalytical Assays

Soukka

Rantanen

Kuningas

2008

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Upconverting phosphors (UCPs) are very attractive reporters for fluorescence resonance energy transfer (FRET)-based bioanalytical assays. The large anti-Stokes shift and capability to convert near-infrared to visible light via sequential absorption of multiple photons enable complete elimination of autofluorescence, which commonly impairs the performance of fluorescence-based assays. UCPs are ideal donors for FRET, because their very narrow-banded emission allows measurement of the sensitized acceptor emission, in principle, without any crosstalk from the donor emission at a wavelength just tens of nanometers from the emission peak of the donor. In addition, acceptor dyes emitting at visible wavelengths are essentially not excited by near-infrared, which further emphasizes the unique potential of upconversion FRET (UC-FRET). These characteristics result in favorable assay performance using detection instrumentation based on epifluorometer configuration and laser diode excitation. Although UC-FRET is a recently emerged technology, it has already been applied in both immunoassays and nucleic acid hybridization assays. The technology is also compatible with optically difficult biological samples, such as whole blood. Significant advances in assay performance are expected using upconverting lanthanide-doped nanocrystals, which are currently under extensive research. UC-FRET, similarly to other fluorescence techniques based on resonance energy transfer, is strongly distance dependent and may have limited applicability, for example in sandwich-type assays for large biomolecules, such as viruses. In this article, we summarize the essentials of UC-FRET, describe its current applications, and outline the expectations for its future potential.

show abstract

Luminescent oxygen channeling assay (LOCI): sensitive, broadly applicable homogeneous immunoassay method

Cited by 231 publications

References 0 publications

Targeting DNA binding proteins for cancer therapy

Targeting DNA binding proteins for cancer therapy

Pharmacokinetics following continuous subcutaneous insulin infusion of insulin aspart with or without initial subcutaneous bolus

Photon Upconversion in Homogeneous Fluorescence‐based Bioanalytical Assays

Contact Info

Product

Resources

About